Abeona Therapeutics Inc [ABEO] stock is trading at $5.66, up 2.17%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ABEO shares have gain 6.39% over the last week, with a monthly amount drifted -13.32%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Oppenheimer started tracking the stock with Outperform rating on March 05, 2025, and set its price target to $16. On July 03, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $15 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $21 on May 30, 2024. Cantor Fitzgerald upgraded its rating to a Overweight but $4 remained the price target by the analyst firm on November 11, 2020. B. Riley FBR started tracking with a Buy rating for this stock on September 18, 2020, and assigned it a price target of $5. In a note dated February 10, 2020, SVB Leerink initiated an Outperform rating and provided a target price of $6 on this stock.
Abeona Therapeutics Inc [ABEO] stock has fluctuated between $3.93 and $7.54 over the past year. Currently, Wall Street analysts expect the stock to reach $20 within the next 12 months. Abeona Therapeutics Inc [NASDAQ: ABEO] shares were valued at $5.66 at the most recent close of the market. An investor can expect a potential return of 253.36% based on the average ABEO price forecast.
Analyzing the ABEO fundamentals
Gross Profit Margin for this corporation currently stands at 0.22% with Operating Profit Margin at -14.38%, Pretax Profit Margin comes in at 14.04%, and Net Profit Margin reading is 11.05%. To continue investigating profitability, this company’s Return on Assets is posted at 0.23, Equity is 0.78 and Total Capital is -0.35. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.15.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.51 points at the first support level, and at 5.37 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.76, and for the 2nd resistance point, it is at 5.87.
Ratios To Look Out For
For context, Abeona Therapeutics Inc’s Current Ratio is 6.73. Further, the Quick Ratio stands at 6.65, while the Cash Ratio is 4.74. Considering the valuation of this stock, the price to sales ratio is 725.58, the price to book ratio is 1.77 and price to earnings (TTM) ratio is 8.97.
Transactions by insiders
Recent insider trading involved O’Malley Brendan M., SVP, Chief Legal Officer, that happened on Sep 29 ’25 when 9366.0 shares were sold. Chief Executive Officer, Seshadri Vishwas completed a deal on Sep 30 ’25 to sell 25000.0 shares. Meanwhile, Chief Executive Officer Seshadri Vishwas sold 19274.0 shares on Sep 29 ’25.
